


# Drug Discovery Today

## INSTRUCTIONS FOR AUTHORS



DRUG DISCOVERY  
TODAY

Submission to *Drug Discovery Today* is **by invitation only**. If you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references. Information on how to submit a proposal can be found at: <http://www.drugdiscoverytoday.com/submit-a-paper/>

<b>Drug Discovery Today article types</b>	<b>Length</b>
<p><b>Guest Editorial</b> articles provide a forum for a personal perspective on contemporary issues and controversies – something you are passionate about or that you think our readers will find thought-provoking.</p>	<ul style="list-style-type: none"> <li>• Max. 1500 words</li> <li>• Max. 10 references</li> <li>• 1 portrait photograph of corresponding author</li> </ul>
<p><b>Short Reviews</b> cover fast-moving recent research topics and form the backbone of <i>Drug Discovery Today</i> content. There are three categories of short reviews:</p> <p><b>Gene to Screen:</b> reviews dealing with the earliest part of drug discovery and all aspects involved in target identification, validation and assay development, particularly advances in genomics and proteomic technologies.</p> <p><b>Informatics:</b> reviews focusing on the latest developments and advances in computational drug discovery.</p> <p><b>Post Screen:</b> reviews covering the science from hit identification to candidate selection, clinical trial design and patent issues as well as associated technologies and business strategies.</p> <p><b>Short Reviews</b> should provide a brief overview of the background and then concentrate on setting recent findings (past 1-2 years) in context. Although they may often tackle controversial topics, they must give a balanced view of developments and authors must never concentrate unduly on their own research. However, they should allow room for some speculation and debate. Articles should be preceded by an abstract of ~100 words. Additional explanatory text or definitions of specialist terms can be put in boxes. The Editor reserves the right to request that reviews be shortened or lengthened.</p>	<ul style="list-style-type: none"> <li>• 3500 words</li> <li>• Max. 60 references</li> <li>• Max. 4 figures, boxes or tables</li> <li>• ~100-word abstract</li> <li>• 25-30-word teaser</li> <li>• 4 or 5 highlight statements of not more than 85 characters and spaces</li> </ul>
<p><b>Keynote Reviews</b> cover topics in a broad, authoritative, timely and comprehensive manner and are longer than the traditional Short Reviews. They should provide a critical and comprehensive overview of the field, discussing important background information, key concepts and summaries of latest developments. Authors must give a balanced view of developments and must never concentrate unduly on their own research. Articles should be preceded by an abstract of ~100 words and a short (~100 words) author biography and photo. Authors are encouraged to</p>	<ul style="list-style-type: none"> <li>• 6000-7000 words</li> <li>• Max. 100 references</li> <li>• Max. 7 figures, boxes or tables</li> <li>• ~100-word abstract</li> <li>• 25-30-word teaser</li> <li>• ~100-word author biogs (up to three biogs only)</li> </ul>

include more figures, boxes and tables than might traditionally be found in Short Reviews. In addition, a glossary containing definitions of specialist terms and a box containing key resources (*i.e.* books, URLs) relevant to the topic should be included

- Author photographs (up to three photos only)
- 4 or 5 highlight statements of not more than 85 characters and spaces

**Foundation Reviews** provide an introduction and comprehensive review of fundamental principles in drug discovery, forming an indispensable educational resource. These articles introduce beginners in the field to concepts and methods used in drug discovery whilst also providing a valuable tool for more experienced workers. These articles should be written in an accessible manner and provide important background information, a review of theory, application and methods in drug discovery, as well as a discussion of historical perspectives and future challenges. Authors are encouraged to include explanatory figures, boxes and tables. In addition, a glossary containing definitions of specialist terms and a box containing key resources (*i.e.* books, URLs) relevant to the topic should be included. Articles should be preceded by an abstract of ~100 words and a short (~100 words) author biography and photo.

- 6000–7000 words
- Max. 100 references
- Max. 7 figures, boxes or tables
- ~100-word abstract
- 25–30-word teaser
- ~100-word author biogs (up to three biogs only)
- Author photographs (up to three photos only)
- 4 or 5 highlight statements of not more than 85 characters and spaces

**Features** are opinion articles on controversial topics or recent developments in the industry, or can cover strategic industry issues, new areas of research, profiles of new research organisations or industry trends. They should stimulate debate, cover controversial topics that are being hotly debated, present new models or hypotheses (along with suggestions for future experiments), or speculate on the meaning/interpretation of some new data. Articles that merely outline recent advances in a field rather than give an *opinion* on them are not suitable for this section.

- Max. 2500 words
- Max. 30 references
- Max. 3 figures
- 4 or 5 highlight statements of not more than 85 characters and spaces

**Biotech focus** articles provide an overview of activities within the pharmaceutical biotechnology sector, focusing on recent developments, strategic issues or specific geographical hotspots. These articles can highlight advances and implications of new developments to this sector, can stimulate debate by covering controversial topics, or provide a forum for future perspectives and directions. Articles that focus on specific biotechnology regions should describe an overview of the biotechnology activities within that region. They should report the local research expertise, and provide readers with a general background of the different companies and their particular strengths. In addition, a short description of how

- Max. 2500 words
- Max. 4 figures, boxes or tables
- Max. 5 references

the area developed (for example, as a result of spin-offs from a local university) would be of interest. Aerial photographs of the biotechnology park can be included for illustrative purposes, or regional maps.

## Please submit completed manuscripts via our EVISE site

You will have been given instructions on how to access the EVISE site when you received your formal invitation to submit.

For specific instructions on how to submit via EVISE please see:

<https://www.elsevier.com/editors/evise>

For queries on these instructions please contact our Editorial Office:

E-mail: [DDT@drugdiscoverytoday.com](mailto:DDT@drugdiscoverytoday.com)

Please note that manuscripts that significantly exceed the stated length will be returned to the author. Please provide current contact details for **3–4 suitable referees**. Although there is no guarantee that we will approach these specific individuals, the provision of contact details may help to ensure rapid progress through the peer-review process.

If you have any difficulties preparing your text or figures, please contact the editorial office for clarification.

This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. [More information](#) on types of peer review.

## Ethics in Publishing

For information on Ethics in Publishing and Ethical guidelines for journal publication see <http://www.elsevier.com/publishingethics> and <http://www.elsevier.com/ethicalguidelines>.

## Conflicts of Interest

All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also <http://www.elsevier.com/conflictsofinterest>.

## Informed Consent

Patients have a right to privacy that should not be violated without informed consent. Identifying information, including names, initials, or hospital numbers, should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that a patient whose identity was confirmed be shown in the published article. Authors should disclose to these patients whether any

potential identifiable material might be available via the Internet as well as in print after publication. Patient consent should be written and archived with the authors, and the authors should provide the journal with a written statement that attests that they have received and archived written patient consent.

Nonessential identifying details should be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are de-identified, authors should provide assurance that such changes do not distort scientific meaning.

When informed consent has been obtained, it should be indicated in the published article.

See ICMJE. Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals, as updated December 2014, and available from: <http://www.ICMJE.org>.

## Statement of Human and Animal Rights

When reporting research involving human data, authors should indicate whether the procedures followed have been assessed by the responsible review committee (institutional and national), or if no formal ethics committee is available, were in accordance with the Helsinki Declaration as revised in 2013 ([www.wma.net/en/30publications/10policies/b3/index.html](http://www.wma.net/en/30publications/10policies/b3/index.html)). If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. Approval by a responsible review committee does not preclude editors from forming their own judgment whether the conduct of the research was appropriate.

When reporting experiments on animals, authors should be asked to indicate whether the institutional and national guide for the care and use of laboratory animals was followed.

See International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals, as updated December 2014, and available from: <http://www.ICMJE.org>.

## Submission declaration

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder

## Authors

Please provide the names of all authors in full, including first name. No more than five authors should be listed (only those who contributed to the actual writing of the manuscript, rather than members of the laboratory contributing to primary work).

Anyone else who contributed to the article can be thanked in the acknowledgements section.

## Changes to authorship

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

*Before the accepted manuscript is published in an online issue:* Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

*After the accepted manuscript is published in an online issue:* Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

## Copyright

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright see <http://www.elsevier.com/copyright>). Acceptance of the agreement will ensure the widest possible dissemination of information. An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult <http://www.elsevier.com/permissions>). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <http://www.elsevier.com/permissions>

## Retained author rights

As an author you (or your employer or institution) retain certain rights; for details you are referred to: Subscription articles please see <http://www.elsevier.com/authorsrights>. Open access articles please see <http://www.elsevier.com/OAauthoragreement>.

## Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. If the funding source(s) had no such involvement then this should be stated. Please see <http://www.elsevier.com/funding>.

## Funding body agreements and policies

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as

conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.

## Language and language services

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who require information about language editing and copyediting services pre- and post-submission please visit <http://www.elsevier.com/languageediting> or our customer support site at <http://epsupport.elsevier.com> for more information.

## Submission

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. **Please do NOT submit .PDF files.** All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail, removing the need for a paper trail.

## Use of word processing software

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. Do not embed "graphically designed" equations or tables, but prepare these using the word processor's facility. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: <http://www.elsevier.com/guidepublication>). Do not import the figures into the text file but, instead, indicate their approximate locations directly in the electronic text and on the manuscript.

Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text.

See also the section on Electronic illustrations.

To avoid unnecessary errors you are strongly advised to use the "spell-check" and "grammar-check" functions of your word processor.

## Graphical abstract

A Graphical abstract is optional and should summarize the contents of the paper in a concise, pictorial form designed to capture the attention of a wide readership online. Authors must provide images that clearly represent the work described in the paper. Graphical abstracts should be submitted as a separate file in the

online submission system. Maximum image size: 400 × 600 pixels (h × w, recommended size 200 × 500 pixels). Preferred file types: TIFF, EPS, PDF or MS Office files. See <http://www.elsevier.com/graphicalabstracts> for examples.

## Research highlights

Research highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate file in the online submission system. Please use 'Research highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters per bullet point including spaces). See <http://www.elsevier.com/researchhighlights> for examples.

## Video data

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a maximum size of 10 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at <http://www.elsevier.com/artworkinstructions>. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

## Supplementary data

Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at <http://www.elsevier.com/artworkinstructions>.

## AudioSlides

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers

understand what the paper is about. More information and examples are available at <http://www.elsevier.com/audioslides>. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

## Proofs

One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author or, a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download Adobe Reader version 7 (or higher) available free from <http://get.adobe.com/reader>. Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site: <http://www.adobe.com/products/reader/tech-specs.html>.

If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof, scan the pages and e-mail. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately – please let us have all your corrections within 48 hours. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.

## Online proof correction

Corresponding authors will receive an e-mail with a link to our ProofCentral system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF. We will do everything possible to get your article published quickly and accurately - please upload all of your corrections within 48 hours. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.

## Use of the Digital Object Identifier

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. The correct format for citing a DOI is shown as follows (example taken from a document from DDT): [doi:10.1016/j.drudis.2015.04.010](https://doi.org/10.1016/j.drudis.2015.04.010) When you use the DOI to create URL hyperlinks to documents on the web, they are guaranteed never to change.

## Open Access

This journal offers authors two choices to publish their research:

Open Access	Subscription
Articles are freely available to both subscribers and the wider public with permitted reuse.	Articles are made available to subscribers as well as developing countries and patient groups through our <a href="#">access programs</a> .
An <a href="#">Open Access publication fee</a> is payable by authors or their research funder.	No Open Access publication fee.

In accordance with Funding Body requirements, Elsevier does offer alternative Open Access publishing options. Visit <http://www.elsevier.com/openaccess> for full information.

Your publication choice will have no effect on the peer review process or acceptance of your submission.

### Details on Open Access Articles:

#### User Rights

All articles published Open Access will be immediately and permanently free for everyone to read and download. We offer authors a choice of user licenses, which define the permitted reuse of articles (see <http://www.elsevier.com/openaccesslicenses>). We are continuously working with our author communities to select the best choice of license options, currently being defined for this journal as follows:

- Creative Commons Attribution (CC-BY)
- Creative Commons Attribution-Non Commercial-ShareAlike (CC BY-NC-SA)
- Creative Commons Attribution-NonCommercial-NoDerivs (CC-BY-NC-ND)

#### Open Access Publication Fee

To provide Open Access, this journal has a publication fee which needs to be met by the authors or their research funders for each article published Open Access.

The Open Access publication fee for this journal is **\$USD 3,750**, excluding taxes.

#### Funding Body Agreements

Elsevier has established [agreements with funding bodies](#), including Wellcome Trust and Research Councils UK. This ensures authors can comply with funding body Open Access policies and may also be reimbursed for their

publication fees.

## Checklist for Authors: *Drug Discovery Today*

(Please tick the boxes once the following have been included in your manuscript)

### ● Before you begin submission

- Source files for the manuscript, figures and tables
- File containing 3 to 5 research highlights (of no more than 85 characters and spaces)
- Names and e-mail addresses of 3 or 4 referees.
- Optional: graphical abstract, video abstract and supplementary data files

### ● Title page (page 1)

- Short title (<8 words long, enticing, relevant to the content).
- Authors' names (no more than 5 names, first names and surnames in full, with middle initials).
- Authors' current addresses.
- One corresponding e-mail address written as: *Corresponding author*: Smith, A.B. (absmith@ucl.ac.uk).
- Keywords (6 maximum) for indexing purposes.
- A teaser (1 sentence, 25–30 words maximum) to convey to the reader why the article is relevant and interesting.

### ● Main text (page 2)

**For details on word count, please see article type table.**

The word count represents the number of words in the body of the text and excludes the abstract, figure legends, text boxes and reference list.

- Abstract: all Review articles should be prefaced by an abstract. This should attract the reader's interest and contain sufficient information for the reader to be able to appreciate the relevance of the article. It should include a brief description of the topic, background information necessary to appreciate the importance of the discussion, and bold statements of the main conclusions or predictions, rather than promises that a particular subject 'will be discussed'. References should not be included and abbreviations avoided. The abstract should be no more than 120 words.
- Introductory section; no heading required
- Subheadings: 4–6 short descriptive subheadings should be used to break up the text into logical sections. Second-level subheadings can be used if necessary.

- Conclusion: the article should finish with a paragraph emphasizing the prospects for future research as well as summarizing the current state of knowledge.
- Citing references: please use numbers in square brackets, in order of citation: e.g. [1] [2,3] [4–7], not alphabetical. If tables and figure legends contain any refs in addition to those cited in the main text, main text refs must be numbered first, followed by additional refs in the tables, followed by additional refs in the figure legends.
- Acknowledgements: placed before reference list, should not acknowledge grants or original research contributors.
- Algebra: numerical variables in italic; categories and groups in roman; vectors in bold
- Define all abbreviations on first mention

### ● Reference lists

**How many references? Please see Article type table for number of references allowed.**

- Unpublished work, PhD theses and URLs/website addresses must be cited in main text, not in reference lists.
- Unpublished work: cited in main text in parentheses as: (Q. Cumber-Patch *et al.*, unpublished).
- PhD theses: cited in main text in parentheses: (R. Arthur Goode, PhD thesis, University of Hawaii, 1988).
- URLs/website addresses: cited in main text in parentheses: (see: <http://www.xxx.yyy.zzz>).
- References in main text, boxes and figures are numbered, and listed at the end of the main text.
- In tables, references should be cited in numbers, in a separate column, and listed at the end of the main text.
- References listed in order of citation, not alphabetically, with one reference per number.
- For journal references:** please give authors' names (if two authors, print both names separated by 'and'; if three or more authors, use *et al.* after first author); date (in parentheses); title (in roman text); abbreviate journal name using *Biological Abstracts*; volume; and complete page range. For example:
  - 1 Gold, B. (2002) Effect of cationic charge localization on DNA structure. *Biopolymers* 65, 173–179
  - 2 Han, Y. and Barillas-Mury, C. (2002) Implications of Time Bomb model of ookinete invasion of midgut cells. *Insect Biochem. Mol. Biol.* 32, 1311
  - 3 Gruber, D.M. *et al.* (1999) Progesterone and neurology. *Gynecol. Endocrinol.* 4, 41–45
  - 4 Jovani, R. Malaria transmission, sex ratio, and erythrocytes with two gametocytes. *Trends Parasitol.* (in press)
- For online journal references:** please give authors' names (as above); date (in parentheses); title (in roman text); abbreviate journal name using *Biological Abstracts*; the digital object identifier (DOI) number;

and the website of the journal. For example:

5 Jiang, J.C. *et al.* (2000) An intervention resembling caloric restriction prolongs life span and retards aging in yeast. *FASEB J.* DOI: 10.1096/fj.00-242fje (<http://www.fasebj.org>)

**For book references:**

For whole books: please give editors' names; date (in parentheses); title (in *italics*); and publisher. For example:

1 Chowdhury, N. and Alonso Aguirre, A., eds (2001) *Helminths of Wildlife*, Science Publishers Inc.

For book chapters: please give chapter authors; date (in parentheses); chapter title; book title (in *italics*); editors' names; page numbers and publisher. For example:

35 Clutton-Brock, T. and Godfray, H.C.J. (1991) Parental investment. In *Behavioural Ecology* (3rd edn) (Krebs, J.R. and Davies, N.B., eds), pp. 234–262, Blackwell

**For patent references:**

23 Bloggs, J. *et al.* Company name that actually owns the patent. Title of patent, Code

## ● Accession numbers

Accession numbers are unique identifiers in bioinformatics allocated to nucleotide and protein sequences to allow tracking of different versions of that sequence record and the associated sequence in a data repository [e.g., databases at the National Center for Biotechnical Information (NCBI) at the National Library of Medicine ('GenBank') and the Worldwide Protein Data Bank]. There are different types of accession numbers in use based on the type of sequence cited, each of which uses a different coding. Authors should explicitly mention the *type of accession number together with the actual number*, bearing in mind that an error in a letter or number can result in a dead link in the online version of the article. Please use the following format: accession number type ID: xxxx (e.g., MMDB ID: 12345; PDB ID: 1TUP). Note that in the final version of the *electronic copy*, accession numbers will be linked to the appropriate database, enabling readers to go directly to that source from the article

### **Possible ways of citing accession numbers in the text:**

1 Sequences for introns 1 and 21 (NH0349G04: **accession number** [AC008172.1](#)) sequenced in GenBank.

2 The **accession numbers** for each sequence are as follows: [BAA78620](#) (Amphiox1), [P09022](#) (mouse Hox-A1) and [CAB57787](#) (*Drosophila* Lab).

## ● Additional material (Boxes, Tables and Figures)

**Please see Article Type Table for the number of separate pieces of additional material allowed.**

### **Boxes**

Boxes can be used for additional explanatory material, which, although essential, interrupts the flow of the text (e.g. mathematical models, glossaries, methodologies and historical notes). Can contain figures and tables. Should be <500 words long.

Have you cited all boxes in the main text?

- Please provide a single-sentence title for the box (<8 words), double-space box text (500 words max.).
- Explain all abbreviations at first mention unless already defined in main text.

## Tables

- Have you cited all tables in the text?
- Please provide single-sentence title for the table, double-space and run-on all text.
- Footnotes: help the reader to understand the table without referring to the main text. Use superscript letters<sup>a,b</sup> to refer to footnotes in alphabetical order. All abbreviations, symbols etc. must be explained in a footnote unless abbreviations have been previously defined in the main text.
- References cited in tables should be in a separate column and listed in the main reference list (in sequence from end of main reference list).

## Figures

- Have you cited all figures in the main text and/or box text?
- Have you obtained permission to reproduce copyrighted material (i.e. material, such as figures, tables or excerpts, that has already been published elsewhere) from the copyright owners of that material
- Have you acknowledged, in the figure legend, the original source of previously published material?
- Please supply individual, editable files of each of your figures. These files should be in the format in which they were originally created, rather than imported into other programs. Produce images near to the desired size of the printed version.
- Figure labels: always first letter capital, then remainder lower-case (not bold or italic, except for species).
- Please provide a figure legend to help the reader to understand the figure without referring to the main text, including: a short title; scale bar (if appropriate); references (should be listed in the main reference list, in sequence from end of list); and explain all abbreviations, symbols and colour codes *etc.* Please place figure legends at the end of main text (after reference list) and not next to the figure. Figure legends should concisely describe what is shown in the figure, and should allow the figure to stand alone without reference to the text.
- All abbreviations used in figure are explained in legend.

**For figure submission guidelines please see:**

<http://www.elsevier.com/artworkinstructions>